Company Profile
Candel Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Candel Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Candel Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Candel Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Candel Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
CADL is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Candel's next major step is the pivotal Phase 3 program for aglatimagene besadenovec in non-squamous NSCLC. That is a much more defined event than a broad pipeline update, and it gives the company a real near-term marker for the oncolytic-virus platform.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Candel Therapeutics Announces Pricing of Public Offering
Source: Candel Therapeutics
- 02
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
Source: Candel Therapeutics
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.